This month, Samsung Bioepis announced the European launch of Obodence (60 mg pre-filled syringe) and Xbryk (120 mg vial), ...

One of the most challenging moments in cancer treatment comes when a therapy stops working. In many metastatic cancers, drugs ...

Neighborhood-level social determinants of health were associated with varying cancer risks and greater mortality among kidney ...

A comprehensive ingredient-level analysis of the nine-compound liquid dropper supplement, examining scientific research, ...

While the current approval focuses on the second-line setting, research is already moving into earlier stages of the ...

Beyond hazard ratios, investigators used restricted mean survival time (RMST) analysis to compare survival gains across trialed ICI combinations for mRCC.